Premium
Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency
Author(s) -
Zucker M.,
Seligsohn U.,
Salomon O.,
Wolberg A. S.
Publication year - 2014
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.12600
Subject(s) - medicine , fibrinolysis , fibrin , factor xi , asymptomatic , gastroenterology , fibrinogen , factor xiii , thrombomodulin , von willebrand factor , hemostasis , coagulation , platelet , surgery , immunology , thrombin
Summary Background Factor XI ( FXI ) deficiency is a rare autosomal recessive disorder. Many patients with even very low FXI levels (< 20 IU dL −1 ) are asymptomatic or exhibit only mild bleeding, whereas others experience severe bleeding, usually following trauma. Neither FXI antigen nor activity predicts the risk of bleeding in FXI ‐deficient patients. Objectives (i) Characterize the formation, structure and stability of plasma clots from patients with severe FXI deficiency and (ii) determine whether these assays can distinguish asymptomatic patients (‘non‐bleeders’) from those with a history of bleeding (‘bleeders’). Methods Platelet‐poor plasmas were prepared from 16 severe FXI ‐deficient patients who were divided into bleeders or non‐bleeders, based on bleeding associated with at least two tooth extractions without prophylaxis. Clot formation was triggered by recalcification and addition of tissue factor and phospholipids in the absence or presence of tissue plasminogen activator and/or thrombomodulin. Clot formation and fibrinolysis were measured by turbidity and fibrin network structure by laser scanning confocal microscopy. Results Non‐bleeders and bleeders had similarly low FXI levels, normal prothrombin times, normal levels of fibrinogen, factor VIII , von W illebrand factor and factor XIII , and normal platelet number and function. Compared with non‐bleeders, bleeders exhibited lower fibrin network density and lower clot stability in the presence of tissue plasminogen activator. In the presence of thrombomodulin, seven of eight bleeders failed to form a clot, whereas only three of eight non‐bleeders did not clot. Conclusions Plasma clot structure and stability assays distinguished non‐bleeders from bleeders. These assays may reveal hemostatic mechanisms in FXI ‐deficient patients and have clinical utility for assessing the risk of bleeding.